Novavax’s Covid-19 vaccine is 89 per cent effective and works against the new variants of the virus, according to interim data published from clinical trials in the UK and South Africa.
The US biotech said a trial in partnership with the UK government’s vaccine task force showed 95.6 per cent efficacy against the original strain and 85.6 per cent against B.1.1.7, which was circulating widely in the country during the study.
Novavax said it is preparing for a clinical trial of a booster to target the 501.v2 variant in the second quarter. Vaccine maker Moderna announced a similar plan earlier this week.
您已阅读20%（608字），剩余80%（2398字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。